J. J. Michiels, Z. Berneman, W. Schroyens, H. De Raeve. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Acta Haematol 2015; 133(1): 36-51.

I. A. Cree. The WHO Classification of Haematolymphoid Tumours. Leukemia 2022; 36(7): 1701-1702.

R. C. Skoda, A. Duek, J. Grisouard. Pathogenesis of myeloproliferative neoplasms. Exp Hematol 2015; 43(8): 599-608.

A. Orazi, U. Germing. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008; 22(7): 1308-1319.

H. Pati, K. Kundil Veetil. Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. Indian J Hematol Blood Transfus 2019; 35(1): 3-11.

S. Ferreira Cristina, B. Polo, J. F. Lacerda. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Semin Hematol 2018; 55(4): 215-222.

L. Malcovati, M. G. Della Porta, D. Pietra, E. Boveri, A. Pellagatti, A. Gallì. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009; 114(17): 3538-3545.

S. Schnittger, C. Eder, F. Dicker, V. Grossmann, A. Kohlmann, W. Kern. In BCR-ABL1 Negative Myeloproliferative Neoplasms the Detection of JAK2exon12, MPLW515, CBL, KITD816V, FIP1L1-PDGFRA Mutations Are Closely Linked to Specific Entities, Whereas the JAK2V617F, TET2, or EZH2 Mutations Demonstrate a Broader Diversity: Patterns From Diagnostic Reports of 18,547 Patients Analyzed. Blood 2010; 116(21): 458.

H. Szpurka, R. Tiu, E. Hsi, A. E. Lichtin, M. A. Sekeres, K. S. Theil. Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome. Blood 2005; 106(11): 369.

M. T. Ye, Y. Wang, S. A. Wang, N. Pemmaraju, N. Daver, S. Verstovsek. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma 2020; 61(4): 963-966.

J. F. Rivera, A. J. Baral, F. Nadat, G. Boyd, R. Smyth, H. Patel. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood Adv 2021; 5(7): 1922-1932.

T. Klampfl, H. Gisslinger, A. S. Harutyunyan, H. Nivarthi, E. Rumi, J. D. Milosevic. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369(25): 2379-2390.

J. Nangalia, C. E. Massie, E. J. Baxter, F. L. Nice, G. Gundem, D. C. Wedge. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369(25): 2391-2405.

Y. Pikman, B. H. Lee, T. Mercher, E. McDowell, B. L. Ebert, M. Gozo. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3(7): e270.

J. J. Jeong, X. Gu, J. Nie, S. Sundaravel, H. Liu, W. L. Kuo. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov 2019; 9(6): 778-795.

Y. C. Chia, M. J. Siti Asmaa, M. Ramli, P. Y. Woon, M. F. Johan, R. Hassan. Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology. Diagnostics (Basel) 2023; 13(1): 163.

A. Tefferi, T. L. Lasho, P. Guglielmelli, C. M. Finke, G. Rotunno, Y. Elala. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv 2016; 1(1): 21-30.

X. Yu, W. Li, Q. Deng, L. Li, E. D. Hsi, K. H. Young. MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res 2018; 78(10): 2457-2462.

N. Lu, C. L. Neoh, Z. Ruan, L. Zhao, L. Ying, X. Zhang. Essential Thrombocythaemia with Concomitant Waldenström Macroglobulinaemia: Case Report and Literature Review. Onco Targets Ther 2020; 13: 3431-3435.